PaxMedica

Historical price data

PaxMedica is a focused, clinical-stage biotech advancing PAX-101, an intravenous formulation of the century-old drug suramin, for neurological disorders. The company's strategy is based on the hypothesis that modulating the purinergic signaling pathway can treat core symptoms of Autism Spectrum Disorder (ASD) and Fragile X-associated Tremor/Ataxia Syndrome (FXTAS). Key achievements include completing a Phase 3 trial in ASD and securing Orphan Drug Designation for PAX-101 in FXTAS. Its path forward is defined by advancing its concentrated pipeline through regulatory milestones while navigating the high-risk, high-reward landscape of CNS drug development.

The company's approach is based on the anti-purinergic therapy (APT) hypothesis, targeting dysregulation in the purinergic signaling pathway—a key cellular communication system—using the known P2 receptor antagonist suramin to potentially address neuroinflammation and core symptoms in neurological disorders.

In ASD, PaxMedica competes indirectly with numerous biotechs developing novel mechanisms for core symptoms, in a field with no approved drugs for this endpoint. In FXTAS, it faces little direct competition, with the primary challenge being clinical validation in an untreated orphan disease. The broader competitive pressure is for funding and investor attention.